Ryan M Rivosecchi1, Aris R Arakelians2, John Ryan2, Holt Murray3, Raj Ramanan3, Hernando Gomez3,4, Dennis Phillips5, Christopher Sciortino2, Peter Arlia6, Danielle Freeman6, Penny L Sappington7, Pablo G Sanchez1. 1. Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA. 2. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. 3. Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. 4. Center for Critical Care Nephrology and the CRISMA Center, University of Pittsburgh, Pittsburgh, PA. 5. Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. 6. Perfusion Services, University of Pittsburgh Medical Center, Pittsburgh, PA. 7. Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, WV.
Abstract
OBJECTIVES: Extracorporeal membrane oxygenation is a life-sustaining therapy for severe respiratory failure. Extracorporeal membrane oxygenation circuits require systemic anticoagulation that creates a delicate balance between circuit-related thrombosis and bleeding-related complications. Although unfractionated heparin is most widely used anticoagulant, alternative agents such as bivalirudin have been used. We sought to compare extracorporeal membrane oxygenation circuit thrombosis and bleeding-related outcomes in respiratory failure patients receiving either unfractionated heparin or bivalirudin for anticoagulation on venovenous extracorporeal membrane oxygenation support. DESIGN: Retrospective cohort study. SETTING: Single-center, cardiothoracic ICU. PATIENTS: Consecutive patients requiring venovenous extracorporeal membrane oxygenation who were maintained on anticoagulation between 2013 and 2020. INTERNVENTIONS: IV bivalirudin or IV unfractionated heparin. MEASUREMENTS AND MAIN RESULTS: Primary outcomes were the presence of extracorporeal membrane oxygenation in-circuit-related thrombotic complications and volume of blood products administered during extracorporeal membrane oxygenation duration. One hundred sixty-two patients receiving unfractionated heparin were compared with 133 patients receiving bivalirudin for anticoagulation on venovenous extracorporeal membrane oxygenation. In patients receiving bivalirudin, there was an overall decrease in the number of extracorporeal membrane oxygenation circuit thrombotic complications (p < 0.005) and a significant increase in time to circuit thrombosis (p = 0.007). Multivariable Cox regression found that heparin was associated with a significant increase in risk of clots (Exp[B] = 2.31, p = 0.001). Patients who received bivalirudin received significantly less volume of packed RBCs, fresh frozen plasma, and platelet transfusion (p < 0.001 for each). There was a significant decrease in the number major bleeding events in patients receiving bivalirudin, 40.7% versus 11.7%, p < 0.001. CONCLUSIONS: Patients receiving bivalirudin for systemic anticoagulation on venovenous extracorporeal membrane oxygenation experienced a decrease in the number of extracorporeal membrane oxygenation circuit-related thrombotic events as well as a significant decrease in volume of blood products administered.
OBJECTIVES: Extracorporeal membrane oxygenation is a life-sustaining therapy for severe respiratory failure. Extracorporeal membrane oxygenation circuits require systemic anticoagulation that creates a delicate balance between circuit-related thrombosis and bleeding-related complications. Although unfractionated heparin is most widely used anticoagulant, alternative agents such as bivalirudin have been used. We sought to compare extracorporeal membrane oxygenation circuit thrombosis and bleeding-related outcomes in respiratory failurepatients receiving either unfractionated heparin or bivalirudin for anticoagulation on venovenous extracorporeal membrane oxygenation support. DESIGN: Retrospective cohort study. SETTING: Single-center, cardiothoracic ICU. PATIENTS: Consecutive patients requiring venovenous extracorporeal membrane oxygenation who were maintained on anticoagulation between 2013 and 2020. INTERNVENTIONS: IV bivalirudin or IV unfractionated heparin. MEASUREMENTS AND MAIN RESULTS: Primary outcomes were the presence of extracorporeal membrane oxygenation in-circuit-related thrombotic complications and volume of blood products administered during extracorporeal membrane oxygenation duration. One hundred sixty-two patients receiving unfractionated heparin were compared with 133 patients receiving bivalirudin for anticoagulation on venovenous extracorporeal membrane oxygenation. In patients receiving bivalirudin, there was an overall decrease in the number of extracorporeal membrane oxygenation circuit thrombotic complications (p < 0.005) and a significant increase in time to circuit thrombosis (p = 0.007). Multivariable Cox regression found that heparin was associated with a significant increase in risk of clots (Exp[B] = 2.31, p = 0.001). Patients who received bivalirudin received significantly less volume of packed RBCs, fresh frozen plasma, and platelet transfusion (p < 0.001 for each). There was a significant decrease in the number major bleeding events in patients receiving bivalirudin, 40.7% versus 11.7%, p < 0.001. CONCLUSIONS:Patients receiving bivalirudin for systemic anticoagulation on venovenous extracorporeal membrane oxygenation experienced a decrease in the number of extracorporeal membrane oxygenation circuit-related thrombotic events as well as a significant decrease in volume of blood products administered.
Authors: Matteo Di Nardo; Ali H Ahmad; Pietro Merli; Matthew S Zinter; Leslie E Lehman; Courtney M Rowan; Marie E Steiner; Sangeeta Hingorani; Joseph R Angelo; Hisham Abdel-Azim; Sajad J Khazal; Basirat Shoberu; Jennifer McArthur; Rajinder Bajwa; Saad Ghafoor; Samir H Shah; Hitesh Sandhu; Karen Moody; Brandon D Brown; Maria E Mireles; Diana Steppan; Taylor Olson; Lakshmi Raman; Brian Bridges; Christine N Duncan; Sung Won Choi; Rita Swinford; Matt Paden; James D Fortenberry; Giles Peek; Pierre Tissieres; Daniele De Luca; Franco Locatelli; Selim Corbacioglu; Martin Kneyber; Alessio Franceschini; Simon Nadel; Matthias Kumpf; Alessandra Loreti; Roelie Wösten-Van Asperen; Orsola Gawronski; Joe Brierley; Graeme MacLaren; Kris M Mahadeo Journal: Lancet Child Adolesc Health Date: 2021-12-09
Authors: Marina Pieri; Vittoria Donatelli; Maria Grazia Calabrò; Anna Mara Scandroglio; Federico Pappalardo; Alberto Zangrillo Journal: J Cardiothorac Vasc Anesth Date: 2021-09-24 Impact factor: 2.894
Authors: Jeffrey Javidfar; Akram M Zaaqoq; Michael H Yamashita; Greg Eschun; Jeffrey P Jacobs; Silver Heinsar; Jeremiah W Hayanga; Giles J Peek; Rakesh C Arora Journal: JTCVS Tech Date: 2021-10-28
Authors: René M'Pembele; Sebastian Roth; Aljoscha Metzger; Anthony Nucaro; Alexandra Stroda; Amin Polzin; Markus W Hollmann; Giovanna Lurati Buse; Ragnar Huhn Journal: Thromb J Date: 2022-07-28
Authors: Alfred H Stammers; Eric A Tesdahl; Anthony K Sestokas; Linda B Mongero; Kirti Patel; Shannon Barletti; Michael S Firstenberg; James D St Louis; Ankit Jain; Caryl Bailey; Jeffrey P Jacobs; Samuel Weinstein Journal: Perfusion Date: 2022-08-09 Impact factor: 1.581
Authors: Katherine Giuliano; Benjamin F Bigelow; Eric W Etchill; Ana K Velez; Chin Siang Ong; Chun W Choi; Errol Bush; Sung-Min Cho; Glenn J R Whitman Journal: Crit Care Explor Date: 2021-07-13